Liposomal MUC1/PET-lipid A Vaccine ONT-10 clinical trials
Also written ONT-10.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How each study uses Liposomal MUC1/PET-lipid A Vaccine ONT-10 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ONT-10
- 2
Studies by the year they started
3 studies that test it; most in 2012 (1)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Liposomal MUC1/PET-lipid A Vaccine ONT-10 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Phase 1 Study of ONT-10 in Patients With Solid TumorsCompletedPhase 1Cascadian Therapeutics Inc.NCT01556789Written as ONT-10How we know
- Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast CancerCompletedPhase 1Cascadian Therapeutics Inc.NCT02270372Written as ONT-10, Varlilumab combinationHow we know
- Phase 1b Maintenance Therapy Study of ONT-10 in Patients With Solid TumorsCompletedPhase 1Cascadian Therapeutics Inc.NCT01978964Written as ONT-10How we know